NCT04991831 - A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Tremor Associated With Tremor Dominant Parkinson's Disease

Interventions

DEVICE

Unilateral thalamotomy

Unilateral thalamotomy using focused ultrasound for the treatment of medication-refractory tremor dominant idiopathic Parkinson's Disease.

Trial Locations (8)

RECRUITING

Weill Cornell Medicine, New York

RECRUITING

Novant Health Brain & Spine Surgery, Huntsville

RECRUITING

Miami Neuroscience Institute Baptist Health, Miami

RECRUITING

Cleveland Clinic Foundation, Cleveland

RECRUITING

Miami Valley Hospital, Fairborn

RECRUITING

Rush University, Chicago

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

University of Dundee, Dundee